Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma
Background: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving survival rates. Objectives: We analyzed the impact of eradication by interferon (IFN)-free dir...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848251324094 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850225531432206336 |
|---|---|
| author | Yuko Nagaoki Kenji Yamaoka Yasutoshi Fujii Shinsuke Uchikawa Hatsue Fujino Atsushi Ono Eisuke Murakami Tomokazu Kawaoka Daiki Miki Hiroshi Aikata Clair Nelson Hayes Masataka Tsuge Shiro Oka |
| author_facet | Yuko Nagaoki Kenji Yamaoka Yasutoshi Fujii Shinsuke Uchikawa Hatsue Fujino Atsushi Ono Eisuke Murakami Tomokazu Kawaoka Daiki Miki Hiroshi Aikata Clair Nelson Hayes Masataka Tsuge Shiro Oka |
| author_sort | Yuko Nagaoki |
| collection | DOAJ |
| description | Background: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving survival rates. Objectives: We analyzed the impact of eradication by interferon (IFN)-free direct-acting antiviral (DAA) therapy on clinical outcomes of patients with HCV-associated HCC who underwent curative treatment. Design: This was a retrospective study. Methods: We retrospectively reviewed 109 consecutive patients with sustained virologic response with DAA therapy after HCC treatment and analyzed HCC recurrence and overall survival (OS). Among these patients are those with a history of HCC recurrence and curative HCC treatments administered as definitive HCC treatments prior to initiation of DAA therapy. Results: Among 109 patients, 64 received DAA therapy after curative treatment for HCC; the remaining 45 received ⩾2 subsequent treatments for HCC. Cumulative HCC recurrence rates at 1, 3, and 5 years were 23%, 47%, and 56%, respectively. Multivariate analysis identified predictive factors for suppression of HCC recurrence as tumor number (hazard ratio (HR) 2.293 for multiple; p = 0.006) and number of HCC treatments before DAA therapy (HR 2.928 for ⩾2; p = 0.001). Among 64 patients who received curative treatment for HCC, cumulative first HCC recurrence rates at 1, 3, and 5 years were 12%, 34%, and 44%, respectively, second recurrence rates were 11%, 28%, and 39%, and third recurrence rates were 0%, 22%, and 53%, respectively; recurrence tended to be suppressed until 3 years. Cumulative OS rates at 3 and 5 years were 87% and 75%, respectively. On multivariate analysis, tumor number (HR 2.452 for single; p = 0.026) was the only independent predictor of OS. Conclusion: DAA therapy after curative treatment for HCC suppresses HCC recurrence in the long term, but recurrence was higher in patients with a history of many HCC treatments. |
| format | Article |
| id | doaj-art-b321dd6d70d6404ab7c3a237ae8bfb06 |
| institution | OA Journals |
| issn | 1756-2848 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj-art-b321dd6d70d6404ab7c3a237ae8bfb062025-08-20T02:05:20ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482025-03-011810.1177/17562848251324094Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinomaYuko NagaokiKenji YamaokaYasutoshi FujiiShinsuke UchikawaHatsue FujinoAtsushi OnoEisuke MurakamiTomokazu KawaokaDaiki MikiHiroshi AikataClair Nelson HayesMasataka TsugeShiro OkaBackground: It is not clear that antiviral therapy for hepatitis C virus (HCV) after recovery from curative treatment for hepatocellular carcinoma (HCC) has an effect on suppressing recurrence or improving survival rates. Objectives: We analyzed the impact of eradication by interferon (IFN)-free direct-acting antiviral (DAA) therapy on clinical outcomes of patients with HCV-associated HCC who underwent curative treatment. Design: This was a retrospective study. Methods: We retrospectively reviewed 109 consecutive patients with sustained virologic response with DAA therapy after HCC treatment and analyzed HCC recurrence and overall survival (OS). Among these patients are those with a history of HCC recurrence and curative HCC treatments administered as definitive HCC treatments prior to initiation of DAA therapy. Results: Among 109 patients, 64 received DAA therapy after curative treatment for HCC; the remaining 45 received ⩾2 subsequent treatments for HCC. Cumulative HCC recurrence rates at 1, 3, and 5 years were 23%, 47%, and 56%, respectively. Multivariate analysis identified predictive factors for suppression of HCC recurrence as tumor number (hazard ratio (HR) 2.293 for multiple; p = 0.006) and number of HCC treatments before DAA therapy (HR 2.928 for ⩾2; p = 0.001). Among 64 patients who received curative treatment for HCC, cumulative first HCC recurrence rates at 1, 3, and 5 years were 12%, 34%, and 44%, respectively, second recurrence rates were 11%, 28%, and 39%, and third recurrence rates were 0%, 22%, and 53%, respectively; recurrence tended to be suppressed until 3 years. Cumulative OS rates at 3 and 5 years were 87% and 75%, respectively. On multivariate analysis, tumor number (HR 2.452 for single; p = 0.026) was the only independent predictor of OS. Conclusion: DAA therapy after curative treatment for HCC suppresses HCC recurrence in the long term, but recurrence was higher in patients with a history of many HCC treatments.https://doi.org/10.1177/17562848251324094 |
| spellingShingle | Yuko Nagaoki Kenji Yamaoka Yasutoshi Fujii Shinsuke Uchikawa Hatsue Fujino Atsushi Ono Eisuke Murakami Tomokazu Kawaoka Daiki Miki Hiroshi Aikata Clair Nelson Hayes Masataka Tsuge Shiro Oka Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma Therapeutic Advances in Gastroenterology |
| title | Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma |
| title_full | Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma |
| title_fullStr | Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma |
| title_full_unstemmed | Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma |
| title_short | Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma |
| title_sort | impact of viral eradication by direct acting antivirals on clinical outcomes after curative treatment for hepatitis c virus associated hepatocellular carcinoma |
| url | https://doi.org/10.1177/17562848251324094 |
| work_keys_str_mv | AT yukonagaoki impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT kenjiyamaoka impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT yasutoshifujii impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT shinsukeuchikawa impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT hatsuefujino impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT atsushiono impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT eisukemurakami impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT tomokazukawaoka impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT daikimiki impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT hiroshiaikata impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT clairnelsonhayes impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT masatakatsuge impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma AT shirooka impactofviraleradicationbydirectactingantiviralsonclinicaloutcomesaftercurativetreatmentforhepatitiscvirusassociatedhepatocellularcarcinoma |